| CAS NO: | 2134675-36-6 |
| 包装: | 5mg |
| 市场价: | 19800元 |
| Cas No. | 2134675-36-6 |
| 别名 | KO-539 |
| 分子式 | C33H42F3N9O2S2 |
| 分子量 | 717.87 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Ziftomenib (KO-539) is a menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151)[1]. The mixed-lineage leukemia (MLL) protein is a histone methyltransferase critical for the epigenetic regulation of gene transcription. Many acute leukemias, including acute myeloblastic leukemia (AML), acute lymphoblastic leukemia (ALL) and mixed-lineage leukemia (MLL), are characterized by the presence of chimeric MLL fusion proteins that result from chromosomal translocations of the MLL gene located at chromosome 11, band q23 (11q23). MLL fusion proteins lack the original histone methyltransferase activity of the C-terminus of MLL and gain the ability to regulate transcription of numerous oncogenes, including HOX and MEIS1, resulting in increased cell proliferation and decreased cell differentiation, ultimately leading to leukemogenesis[1]. [1]. Tao Wu, et al. Substituted inhibitors of menin-mll and methods of use. WO2017161028A1. |
m.cnreagent.com